Cantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Cantor Fitzgerald has maintained its Neutral rating for Amedisys (NASDAQ:AMED) and raised its price target from $100.00 to $101.00. Amedisys shares are currently trading at $93.61, up 0.11% over the last 24 hours. A move to $101.00 would represent a 7.89% increase from the current share price.
September 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained its Neutral rating for Amedisys and raised its price target. This could potentially lead to a positive impact on the stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Cantor Fitzgerald's decision to maintain a Neutral rating and raise the price target for Amedisys could potentially lead to increased investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100